糖尿病肾病危险因素及血压控制临界值研究

被引:149
作者
李泽宇
刘栋
袁文明
赵占正
机构
[1] 郑州大学第一附属医院肾脏内科
关键词
糖尿病肾病; 高血压; ROC曲线; Logistic模型;
D O I
暂无
中图分类号
R587.2 [糖尿病性昏迷及其他并发症]; R692 [肾疾病];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
目的分析糖尿病肾病的危险因素,并探讨糖尿病肾病患者血压控制的临界值。方法回顾性纳入2011—2012年河南大学第一附属医院住院糖尿病患者375例,收集患者相关临床资料:性别、年龄、糖尿病病程、糖尿病家族史,测量血压,检测空腹血糖、总胆固醇、三酰甘油、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)。24 h尿蛋白<30 mg为非糖尿病肾病组,24 h尿蛋白≥30 mg为糖尿病肾病组。对两组患者上述指标进行对比分析,采用多因素Logistic回归分析糖尿病肾病的相关影响因素。应用受试者工作特征曲线(ROC曲线)分析收缩压(SBP)和舒张压(DBP)诊断糖尿病肾病的临界值。结果非糖尿病肾病组293例,糖尿病肾病组82例。两组患者糖尿病病程、家族史、SBP、DBP、血肌酐、总胆固醇、LDL-C和HDL-C间差异均有统计学意义(P<0.05),空腹血糖和三酰甘油间差异无统计学意义(P>0.05)。Logistic回归分析显示,高水平的SBP(OR=1.057)、血肌酐(OR=1.050)、总胆固醇(OR=2.197)、LDL-C(OR=1.519)是糖尿病肾病的独立危险因素(P<0.05),HDL-C(OR=0.063)是糖尿病肾病的保护因素(P<0.05)。SBP和DBP诊断糖尿病肾病的ROC曲线下面积分别为0.776和0.625,SBP和DBP的临界值分别为139.5、78.5 mm Hg(1 mm Hg=0.133 kPa)。结论高水平的SBP、总胆固醇、LDL-C是糖尿病肾病的危险因素,高HDL-C是糖尿病肾病的保护因素。糖尿病肾病血压控制在140/80 mm Hg以内较适宜。
引用
收藏
页码:2325 / 2328
页数:4
相关论文
共 13 条
[1]
Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes [J].
Jardine, Meg J. ;
Hata, Jun ;
Woodward, Mark ;
Perkovic, Vlado ;
Ninomiya, Toshiharu ;
Arima, Hisatomi ;
Zoungas, Sophia ;
Cass, Alan ;
Patel, Anushka ;
Marre, Michel ;
Mancia, Giuseppe ;
Mogensen, Carl E. ;
Poulter, Neil ;
Chalmers, John .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2012, 60 (05) :770-778
[2]
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.[J].Michael V. Rocco.American Journal of Kidney Diseases.2012, 5
[3]
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis [J].
Singh, Sumeet R. ;
Ahmad, Fida ;
Lal, Avtar ;
Yu, Changhua ;
Bai, Zemin ;
Bennett, Heather .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2009, 180 (04) :385-397
[4]
Standards of medical care in diabetes--2009..[J].Anonymous.Diabetes care.2009, Suppl.1
[5]
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy [J].
Jorsal, Anders ;
Tarnow, Lise ;
Frystyk, Jan ;
Lajer, Maria ;
Flyvbjerg, Allan ;
Parving, Hans-Henrik ;
Vionnet, Nathalie ;
Rossing, Peter .
KIDNEY INTERNATIONAL, 2008, 74 (05) :649-654
[6]
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes [J].
Patel, Anushka ;
MacMahon, Stephen ;
Chalmers, John ;
Neal, Bruce ;
Billot, Laurent ;
Woodward, Mark ;
Marre, Michel ;
Cooper, Mark ;
Glasziou, Paul ;
Grobbee, Diederick ;
Hamet, Pavel ;
Harrap, Stephen ;
Heller, Simon ;
Liu, Lisheng ;
Mancia, Giuseppe ;
Mogensen, Carl Erik ;
Pan, Changyu ;
Poulter, Neil ;
Rodgers, Anthony ;
Williams, Bryan ;
Bompoint, Severine ;
de Galan, Bastiaan E. ;
Joshi, Rohina ;
Travert, Florence .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24) :2560-2572
[7]
Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes [J].
Estacio, Raymond O. ;
Coll, Joseph R. ;
Tran, Zung Vu ;
Schrier, Robert W. .
AMERICAN JOURNAL OF HYPERTENSION, 2006, 19 (12) :1241-1248
[8]
Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial [J].
Berl, T ;
Hunsicker, LG ;
Lewis, JB ;
Pfeffer, MA ;
Porush, JG ;
Rouleau, JL ;
Drury, PL ;
Esmatjes, E ;
Hricik, D ;
Pohl, M ;
Raz, I ;
Vanhille, P ;
Wiegmann, TB ;
Wolfe, BM ;
Locatelli, F ;
Goldhaber, SZ ;
Lewis, EJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07) :2170-2179
[9]
Diabetic nephropathy: Diagnosis, prevention, and treatment [J].
Gross, JL ;
de Azevedo, MJ ;
Silveiro, SP ;
Canani, LH ;
Caramori, ML ;
Zelmanovitz, T .
DIABETES CARE, 2005, 28 (01) :164-176
[10]
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.[J].Scott M. Grundy;James I. Cleeman;C. Noel Bairey Merz;H. Bryan Brewer;Luther T. Clark;Donald B. Hunninghake;Richard C. Pasternak;Sidney C. Smith;Neil J. Stone.Journal of the American College of Cardiology.2004, 3